Centessa Pharmaceuticals plc

NasdaqGS:CNTA 株式レポート

時価総額：US$6.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Centessa Pharmaceuticals マネジメント

マネジメント 基準チェック /24

Centessa Pharmaceuticalsの CEO はMario Accardiで、 Jan2026年に任命され、 の在任期間は 1 年未満です。 は、会社の株式の0.16%を直接所有しており、その価値は$ 9.85M 。経営陣と取締役会の平均在任期間はそれぞれ2年と5.3年です。

主要情報

Mario Accardi

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間less than a year
CEOの所有権0.2%
経営陣の平均在職期間2yrs
取締役会の平均在任期間5.3yrs

経営陣の近況

Recent updates

分析記事 • Oct 28

Health Check: How Prudently Does Centessa Pharmaceuticals (NASDAQ:CNTA) Use Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • Dec 31

Centessa Pharmaceuticals: Orexin Franchise Worth Monitoring

Summary Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily developing its lead orexin agonist, ORX-750. ORX-750 targets narcolepsy types 1 and 2 and idiopathic hypersomnia, showing promising phase 1 results, with phase 2 data expected in 2025. Takeda's TAK-861 success partially de-risks ORX-750, making Centessa a potential acquisition target if ORX-750 proves it is best-in-class. With $500M in cash and a runway into mid-2027, Centessa's phase 2 trial results for ORX-750 are crucial for its future valuation. Read the full article on Seeking Alpha
Seeking Alpha • Sep 25

Centessa Pharmaceuticals: Progressing SerpinPC Through Registrational Trials In Hemophilia B

Summary Centessa Pharma's SerpinPC, a subcutaneous biologic inhibitor, shows promising results in reducing bleeding rates in hemophilia B, with a favorable safety profile. Despite the stock doubling in value, I remain cautious due to the company's unclear business strategy and lack of registrational data. The hemophilia B market is competitive with existing treatments. SerpinPC's unique mechanism and delivery method provide niche advantages but face significant competition. With a $2bn market cap and a cash runway of 6-7 quarters, I will avoid investing until there's more clarity on their strategic direction. Read the full article on Seeking Alpha
Seeking Alpha • Apr 24

Centessa: Hemophilia B Data Readout In 2024 Is Major Turning Point

Summary Centessa Pharmaceuticals plc interim data from the PRESent-2 study, using SerpinPC for the treatment of patients with Hemophilia B without inhibitors, is expected to be released in 2024. PRESent-3 is another registrational study using SerpinPC for the treatment of patients with Hemophilia B, however it is for the targeting of such patients with inhibitors. ORX750 is an oral selective orexin receptor agonist being developed for the treatment of patients with Narcolepsy Type 1; Proof of concept data to be released in second half 2024. LB101 is another product in the pipeline with great potential targeting solid tumors, because it utilizes proven targeted proteins such as PD-L1 and CD47; The PD-L1 blockade occurs first as a block mechanism then with hinges dissolving moves the CD47 into place to perform mechanism of action. Read the full article on Seeking Alpha
Seeking Alpha • Oct 20

Centessa Pharmaceuticals snaps multi-day losing streak; up 10%

For the first time since Oct. 13, Centessa Pharmaceuticals (NASDAQ:CNTA) is showing gains. In Thursday afternoon trading, the biotech is up 10%. There is no news or other catalysts that might explain the jump. However, based on a technical analysis, Centessa (CNTA) deviated two standard deviations lower from its mean touching its lower Bolinger Band level and has snapped up higher, back to its mean level. From market close Oct. 13 through market close Oct. 19, shares fell ~15%. Seeking Alpha views Centessa (CNTA) as a hold with high marks for valuation and growth.
Seeking Alpha • Sep 14

Centessa hemophilia B therapy SerpinPC gets FDA orphan drug status

The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Centessa Pharmaceuticals' (NASDAQ:CNTA) SerpinPC to treat hemophilia B. The U.K.-based company said in a Sept. 14 press release that it plans to begin registrational studies of SerpinPC in Q4 2022. SerpinPC is a biological drug candidate, based on the serpin family of proteins which is designed to allow more thrombin to be generated by inhibiting activated protein C (APC), thus rebalancing coagulation in patients with hemophilia, according to Centessa. "We believe SerpinPC has the potential to offer patients with hemophilia B a convenient subcutaneous option that is designed to prevent and reduce bleeds without the risk of thrombosis," said Centessa CEO Saurabh Saha. The FDA grants orphan drug status to therapies which treat or prevent rare diseases that affect fewer than 200K people in the U.S. The designation provides certain incentives, including up to seven years of market exclusivity, if approved.
Seeking Alpha • Aug 10

Centessa Pharmaceuticals GAAP EPS of -$0.69

Centessa Pharmaceuticals press release (NASDAQ:CNTA): Q2 GAAP EPS of -$0.69. Cash and Cash Equivalents: $484.2 million as of June 30, 2022, which the Company expects will fund operations into 2026, without drawing on the remaining available tranches under the Oberland credit facility.
Seeking Alpha • Dec 23

Checking In On Centessa Pharmaceuticals

Today, we put Centessa Pharmaceuticals in the spotlight for the first time. Centessa has a unique business model, multiple potential shots on goal, is deep in Busted IPO territory and has picked up some recent insider buying. A full investment analysis follows in the paragraphs below.

CEO

Mario Accardi (40 yo)

less than a year
在職期間

Dr. Mario Alberto Accardi, Ph D., MENG, is Co-Founder, Chairman & Director of Orthonika Limited. He was CEO of Orthonika Limited.He served as President of the Orexin Program at Centessa Pharmaceuticals pl...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
John Crowley
Chief Financial Officer2yrsUS$3.84m0%
$ 0
Stephen Kanes
Head of R&D and Chief Medical Officer1.4yrsUS$6.82m0%
$ 0
Mario Accardi
CEO & Directorless than a yearデータなし0.16%
$ 9.9m
Raphael Deferiere
Senior VP & Chief Accounting Officer1.1yrsデータなしデータなし
Tia Bush
Chief Technology & Quality Officer3.3yrsデータなし0.054%
$ 3.4m
Kristen Sheppard
Senior Vice President of Investor Relations & Corporate Communications4yrsデータなしデータなし
Iqbal Hussain
Chief Legal Officer5.3yrsUS$2.05m0.016%
$ 1.0m
Karen Anderson
Chief People Officer3.6yrsデータなし0.043%
$ 2.7m
Gregory Weinhoff
Chief Business Officer2yrsUS$3.31m0%
$ 0
Charlene Stoudt
Senior Vice President of Clinical Development Operations1.7yrsデータなしデータなし
Kimberly McCormick
Senior Vice President of Regulatory Affairs & Medical Writing1.4yrsデータなしデータなし
2.0yrs
平均在職期間
53.5yo
平均年齢

経験豊富な経営陣: CNTAの経営陣は 経験豊富 であると考えられます ( 2年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Mario Accardi
CEO & Directorless than a yearデータなし0.16%
$ 9.9m
Francesco de Rubertis
Independent Non-Executive Chairman of the Board5.6yrsデータなしデータなし
Mary Hedley
Independent Non-Executive Director5.3yrsUS$404.64k0%
$ 0
Brett I. Zbar
Independent Non-Executive Director5.4yrsUS$409.64k0%
$ 0
Arjun Goyal
Independent Non-Executive Director5.4yrsUS$412.14k0.30%
$ 18.7m
Samarth Kulkarni
Independent Non-Executive Director5.3yrsUS$407.14k0%
$ 0
Carol Stuckley
Independent Non-Executive Director5.1yrsUS$414.64k0%
$ 0
Mathias Hukkelhoven
Independent Non-Executive Director3.9yrsUS$399.64k0%
$ 0
5.3yrs
平均在職期間
55yo
平均年齢

経験豊富なボード: CNTAの 取締役会 は 経験豊富 であると考えられます ( 5.3年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/06/25 15:53
終値2026/06/23 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Centessa Pharmaceuticals plc 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11

アナリスト機関
Mayank MamtaniB. Riley Securities, Inc.
Umer RaffatEvercore ISI
Andrea NewkirkGoldman Sachs